Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Isabel Cunningham MD

Isabel Cunningham MD

Adjunct Associate Research Scientist, Division of Hematology Oncology, Columbia University College of Physicians and Surgeons, New York, New York

With broad experience in both academic oncology and clinical research, Dr. Cunningham provides a crucial bridge between community and academic medicine. Dr. Cunningham received her AB from Bryn Mawr College and her MD from Yale University School of Medicine. Her postgraduate training included a fellowship in hematology-oncology and bone marrow transplant at Memorial Sloan-Kettering Cancer Center. Dr. Cunningham has held academic positions at Memorial Sloan-Kettering and several other universities, and she is currently conducting research at Columbia University. She has published extensively and has been a reviewer for Blood, Bone Marrow Transplantation, Experimental Hematology, and Leukemia & Lymphoma.

Positions:
Adjunct Associate Research Scientist, Columbia University

Degrees:
Bryn Mawr College, AB
Yale University School of Medicine, MD

Postgraduate Training:
Resident, Internal Medicine, Presbyterian Hospital, New York
Fellow, Hematology/Oncology, Memorial Sloan-Kettering Cancer Center

Board Certifications:
Internal medicine
Hematology

Clinical Interests:
Hematologic malignancies
Extramedullary Leukemia

Disclosures

Dr. Cunningham does not have any financial disclosures.

Recent Contributions to PracticeUpdate:

  1. Sorafenib Maintenance After Allo-HSCT for AML With FLT3-Internal Tandem Duplication Mutation
  2. Time From Diagnosis to Treatment Does Not Affect the Prognosis of Patients With Newly Diagnosed AML
  3. ASCO 2020: Abstract Recommendations From Dr. Isabel Cunningham for Hematologic Malignancies
  4. CD4/CD8 T-Cell Selection Affects CAR T-Cell Potency and Toxicity
  5. Feasibility and Efficacy of CD19-Targeted CAR T Cells With Concurrent Ibrutinib for CLL After Ibrutinib Failure
  6. Early Treatment With FCR vs Watch and Wait in Patients With Stage Binet A High-Risk CLL
  7. Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia Treated Upfront With Arsenic Trioxide
  8. Loss of X Chromosome Predicts Favorable Prognosis in Female Patients With t(8;21) Acute Myeloid Leukemia
  9. Impact of Conditioning Intensity of Allogeneic Transplantation for AML With Evidence of Residual Disease
  10. Ivosidenib Induces Deep Durable Remissions in Newly Diagnosed IDH1-Mutant AML

Most Read This Week

Recently Updated